Genetic analysis can improve depression therapy

January 12, 2018, Karolinska Institutet
Credit: CC0 Public Domain

The failure of drugs such as SSRIs, used to treat depression, can be a result of genetic variations in patients. Variations within the gene that encodes the CYP2C19 enzyme results in extreme differences in the levels of escitalopram achieved in patients, according to a new study published in The American Journal of Psychiatry. Prescribing the dose of escitalopram based on a patient's specific genetic constitution would greatly improve therapeutic outcomes. The study was conducted at Karolinska Institutet in Sweden in association with researchers at Diakonhjemmet Hospital in Oslo, Norway.

Pharmaceutical treatment of depression commonly makes use of selective serotonin reuptake inhibitors (SSRIs) of which escitalopram is the most frequently administered clinically. However, escitalopram therapy is currently limited by the fact that some do not respond well to the , while others develop adverse reactions requiring discontinuation of treatment.

In order to individualise drug therapy, researchers are attempting to establish genetic biomarkers that can predict an individual's response to drugs. In a recent study, it was discovered that variation in the gene encoding the enzyme responsible for escitalopram metabolism (CYP2C19) is very important in this respect. Individuals with a variant of the gene promoting increased enzyme expression had blood levels of escitalopram too low to impact the depression symptoms, whereas patients with a defective CYP2C19 gene reached drug levels which were too high. Overall, one third of the 2,087 study participants achieved escitalopram blood levels that were either too high or too low.

Interestingly, the researchers found that 30 per cent of the patients carrying gene variants causing excessive or inadequate enzyme levels switched to other drugs within one year, in contrast with only 10 to 12 per cent of patients carrying the common gene.

"Our study shows that genotyping of CYP2C19 could be of considerable clinical value in individualising doses of so that a better all-round antidepressive effect could be achieved for the patients," says Professor Magnus Ingelman-Sundberg at Karolinska Institutet's Department of Physiology and Pharmacology who led the study together with Professor Espen Molden. "Because CYP2C19 is involved in the metabolism of many different SSRIs, the finding is also applicable to other types of antidepressants."

Explore further: Antidepressant does not reduce hospitalization, death for HF patients with depression

More information: Marin M. Jukić et al. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients, American Journal of Psychiatry (2018). DOI: 10.1176/appi.ajp.2017.17050550

Related Stories

Antidepressant does not reduce hospitalization, death for HF patients with depression

June 28, 2016
In a study appearing in the June 28 issue of JAMA, Christiane E. Angermann, M.D., of University Hospital Wurzburg, Germany, and colleagues examined whether 24 months of treatment with the antidepressant escitalopram would ...

Brain stimulation no better than escitalopram for depression

June 29, 2017
(HealthDay)—Escitalopram may outperform transcranial direct-current stimulation (tDCS) in the treatment of depression, according to a study published in the June 29 issue of the New England Journal of Medicine.

High levels of a specific enzyme in fetuses linked to anxiety

July 24, 2013
Mouse embryos with the human enzyme CYP2C19 in the brain develop a smaller hippocampus and anxiety-like behaviour as adults. The results of this new study, which is published in the journal Molecular Psychiatry, agree in ...

Enzyme research provides a new picture of depression

November 29, 2016
Depression is the predominant mental disease and constitutes the most common cause of morbidity in developed countries. Now researchers at Karolinska Institutet have managed to find a connection between development of depression ...

Patients' expectations influence effectiveness of SSRI antidepressants

October 3, 2017
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression and anxiety but their superiority over placebo has been questioned, generating considerable debate among researchers and clinicians. In ...

CYP2C19 polymorphisms impacts citalopram metabolism

December 14, 2015
(HealthDay)—For patients with major depressive disorder, certain CYP2C19 polymorphisms contribute to citalopram (CIT) metabolism, according to research published in the December issue of the Journal of Clinical Pharmacy ...

Recommended for you

New study questions use of talking therapy as a treatment for schizophrenia

July 20, 2018
The findings of the first meta-analysis examining the effectiveness of Cognitive Behavioural Therapy for psychosis (CBTp) on improving the quality of life and functioning and reducing distress of people diagnosed with schizophrenia ...

Perfectionism in young children may indicate OCD risk

July 19, 2018
Studying young children, researchers at Washington University School of Medicine in St. Louis found that kids who possess tendencies toward perfectionism and excessive self-control are twice as likely as other children to ...

Younger children tend to make more informed decisions

July 19, 2018
A new study from the University of Waterloo has found that in some ways, the older you get the worse your decision making becomes.

Finding well-being through an aerial, as opposed to ground-level, view of time

July 19, 2018
Do today and yesterday and tomorrow loom large in your thinking, with the more distant past and future barely visible on the horizon? That's not unusual in today's time-pressed world—and it seems a recipe for angst.

Are you prone to feeling guilty? Then you're probably more trustworthy, study shows

July 19, 2018
It turns out your mother was right: guilt is a powerful motivator.

Using an electronic device counteracts benefits of taking a break in nature, researchers find

July 19, 2018
Being in nature helps restore your brain's ability to focus attention on a task. But if you are checking social media on your phone or answering emails on your laptop – even if you are doing so while surrounded by trees ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.